[A randomized controlled clinical study of cefetamet pivoxil versus cefixime in the treatment of 99 cases bacterial infections].
A randomized controlled clinical study of cefetamet pivoxil (CAT) compared with cefixime (CFX) was conducted to evaluate its safety and efficacy in treating bacterial infections. 99 patients suffering from respiratory and urinary tract infections were enrolled in the study. 10 patients were excluded within the first 72 hrs after initiation of the study. 55 and 54 were evaluated for the safety of CAT and CFX respectively. 51 patients in the CAT group and 48 patients in the CFX group were evaluated for the efficacy. The doage of CAT was 250-500 mg and CFX was 200 mg, twice daily orally for 7-10 days. The results showed that the clinical efficacy rates of CAT and CFX were 94.1% (48/51) and 91.7% (44/48), the bacterial clearance rates were 95.3% and 95.1%, respectively. Adverse drug reactions occurred in 9.1% and 7.4% in the two groups respectively. The study demonstrated that there were no satistical differences between the two groups with respect to clinical efficacy, bacterial clearance and adverse reactions.
Zhao
C
C
Institute of Clinical Pharmacology, Beijing Medical University.
Li
J
J
Hao
F
F
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013297:Streptococcus pyogenes / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology
D002511:Cephalosporins; D020682:Cefixime; D015296:Ceftizoxime; C047445:cefetamet pivoxyl; D002439:Cefotaxime